14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
MBIO vs ABVE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Mustang Bio, Inc. (MBIO) captures the overall head-to-head institutional edge over Above Food Ingredients Inc. (ABVE) on higher Unified Composite conviction (42.9/100 HOLD vs. 39.8/100 SELL) after splitting the core matrix 6–2 (led by Profitability & Quality), while ABVE wins 5–1 across the 6-pillar growth and valuation breakdown. MBIO trades at $0.39 (N/M Forward P/E, 0.0% operating margin) versus ABVE at $0.11 (N/M Forward P/E, -23.2% operating margin).
Growth vs. Quality Trade-Off: MBIO earns the overall head-to-head edge with a stronger Unified Composite Score (42.9/100 HOLD vs. ABVE 39.8/100 SELL) and 0.68β · 87% Vol risk profile, whereas ABVE leads top-line expansion (-45.0% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: MBIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4); meanwhile ABVE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBIO vs ABVE. Trailing 12-month operating profitability (MBIO 0.0% vs ABVE -23.2%) and valuation multiples (MBIO N/M vs ABVE N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Packaged Foods value chain with $30.0M market capitalization and -23.2% operating margin.
OpEx & R&D Reinvestment20.4% of Rev ($60M)
90D Engineering Disclosures0 Published
Investor FAQ MBIO vs ABVE Key Questions & Quantitative Answers
As of Nov 17, 2026, Mustang Bio, Inc. (MBIO) captures the overall head-to-head institutional edge over Above Food Ingredients Inc. (ABVE) on higher Unified Composite conviction (42.9/100 HOLD vs. 39.8/100 SELL) after splitting the core matrix 6–2 (led by Profitability & Quality), while ABVE wins 5–1 across the 6-pillar growth and valuation breakdown. MBIO trades at $0.39 (N/M Forward P/E, 0.0% operating margin) versus ABVE at $0.11 (N/M Forward P/E, -23.2% operating margin). Growth vs. Quality Trade-Off: MBIO earns the overall head-to-head edge with a stronger Unified Composite Score (42.9/100 HOLD vs. ABVE 39.8/100 SELL) and 0.68β · 87% Vol risk profile, whereas ABVE leads top-line expansion (-45.0% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MBIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4); meanwhile ABVE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABVE leads the Growth & Scale pillar: MBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ABVE at -45.0% YoY revenue growth and +0.0% YoY earnings growth on $295M TTM revenue (-2.8% gross margin, -23.2% operating margin). On trailing 12-month operating scale, MBIO generates N/A in USD-normalized revenue versus $295M for ABVE. In operating R&D and SG&A reinvestment, MBIO deploys N/A (0 90-day corporate R&D disclosures) versus 20.4% of Rev ($60M) (0 disclosures) for ABVE.
ABVE screens cheaper on headline valuation multiples. MBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABVE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-13.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MBIO (-43.1% ROE) versus ABVE (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, MBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 87% Vol realized risk). By comparison, ABVE carries 148.3% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.10β · 310% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.